Program
tenofovir alafenamide
Also written as “E/C/F/TAF”, “TAF” and “B/F/TAF”.
Its studies are mostly in Acquired Immunodeficiency Syndrome · Hepatitis B, Chronic · HIV Infections · Hepatitis · Coinfection, led by 7 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Gilead Sciences | 499 open or running | phase 4since Oct 23, 2023 | May 13, 2002 | Jun 2027phase 4 · NCT06337032 |
| Johnson & Johnson | 70 open or running | phase 3since Oct 17, 2014 | Oct 17, 2014 | none ahead |
| Henan Genuine Biotech | 10 open or running | phase 1since May 13, 2025 | May 13, 2025 | none ahead |
| Humanis Saglık Anonim Sirketi | 10 open or running | phase 1since Sep 9, 2024 | Sep 9, 2024 | none ahead |
| New Discovery | 10 open or running | phase 4since Dec 6, 2019 | Dec 6, 2019 | none ahead |
| The Crofoot Research Center | 10 open or running | phase 4since May 12, 2020 | May 12, 2020 | none ahead |
| Xiamen Amoytop Biotech | 11 open or running | no phasesince Nov 24, 2024 | Nov 24, 2024 | May 31, 2029NCT06707922 |
Also a collaborator on its studies: Merck and F-star Therapeutics.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Dec 14, 2011.
- Dec 6, 2019New Discovery’s first study: phase 4 study in Hepatitis B, ChronicNew to New DiscoveryNew Discovery · NCT04201808 · 100 enrolled · China
- Jan 21, 2020Phase 1 study in HealthyJohnson & Johnson · NCT04236453 · 16 enrolled · Netherlands
- May 12, 2020The Crofoot Research Center’s first study: phase 4 study in Acquired Immunodeficiency SyndromeNew to The Crofoot Research CenterThe Crofoot Research Center · NCT04388904 · 75 enrolled · United States
- Dec 3, 2020Phase 1 study in HealthyJohnson & Johnson · NCT04661397 · 37 enrolled · Netherlands
- Aug 2, 2021Phase 3 study in Pre-Exposure Prophylaxis of HIV InfectionGilead Sciences · NCT04994509 · 5,368 enrolled · South Africa, Uganda
- Oct 23, 2023Phase 4 study in HIV-1-infectionGilead Sciences · NCT06104306 · 33 enrolled · United States, Canada, France
- Mar 22, 2024Phase 4 study in HIV-1-infectionGilead Sciences · NCT06337032 · 350 planned · Argentina, Panama, South Africa and more
- Sep 9, 2024Humanis Saglık Anonim Sirketi’s first study: phase 1 study in Chronic Hepatitis B in Adults and Paediatric PatientsNew to Humanis Saglık Anonim SirketiHumanis Saglık Anonim Sirketi · NCT06592300 · 42 enrolled · India
- Oct 4, 2024Phase 3 study in HIV-1-infectionGilead Sciences · NCT06630286 · 609 enrolled · United States, Argentina, Australia and more
- Nov 24, 2024Xiamen Amoytop Biotech’s first study: no phase study in Hepatitis B, ChronicNew to Xiamen Amoytop BiotechXiamen Amoytop Biotech · NCT06707922 · 350 planned · China
- May 13, 2025Henan Genuine Biotech’s first study: phase 1 study in HealthyNew to Henan Genuine BiotechHenan Genuine Biotech · NCT07002268 · 15 enrolled · China
- Jun 27, 2025Phase 1 study in HIV-1-infectionGilead Sciences · NCT07055451 · 16 enrolled · United States, South Africa
- Jun 8, 2026Phase 2 study in HIV-1-infectionGilead Sciences · NCT07645287 · 175 planned · United States, Australia, Canada and more
- Jul 13, 2026Phase 3 study in HIV-1-infectionGilead Sciences · NCT07708727 · 700 planned · United States, Canada, Germany and more
Ahead
- Jun 2027Primary completion: phase 4 study in HIV-1-infectionGilead Sciences · NCT06337032
- Aug 2027Primary completion: phase 2 study in HIV-1-infectionGilead Sciences · NCT07645287
- Mar 2028Primary completion: phase 1 study in HIV-1-infectionGilead Sciences · NCT07055451
- May 31, 2029Primary completion: no phase study in Hepatitis B, ChronicXiamen Amoytop Biotech · NCT06707922
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Human immunodeficiency virus type 1 reverse transcriptase inhibitor; Human immunodeficiency virus type 1 reverse transcriptase inhibitor”ChEMBL 37, by rule
Studies
The newest 60 of 61 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07708727HIV-1-infection · United States, Canada, Germany and more | 3 | Recruiting | Gilead Sciences | Oct 2030 | 700 |
| NCT07645287HIV-1-infection · United States, Australia, Canada and more | 2 | Recruiting | Gilead Sciences | Aug 2027 | 175 |
| NCT07055451HIV-1-infection · United States, South Africa | 1 | Active, not recruiting | Gilead Sciences | Mar 2028 | 16 |
| NCT07002268Healthy · China | 1 | Completed | Henan Genuine Biotech | May 4, 2022 | 15 |
| NCT06707922Hepatitis B, Chronic · China | – | By invitation | Xiamen Amoytop Biotech | May 31, 2029 | 350 |
| NCT06630286HIV-1-infection · United States, Argentina, Australia and more | 3 | Active, not recruiting | Gilead Sciences | Apr 17, 2026 | 609 |
| NCT06592300Chronic Hepatitis B in Adults and Paediatric Patients · India | 1 | Completed | Humanis Saglık Anonim Sirketi | Aug 2, 2024 | 42 |
| NCT06337032HIV-1-infection · Argentina, Panama, South Africa and more | 4 | Recruiting | Gilead Sciences | Jun 2027 | 350 |
| NCT06104306HIV-1-infection · United States, Canada, France | 4 | Completed | Gilead Sciences | Jan 29, 2025 | 33 |
| NCT04994509Pre-Exposure Prophylaxis of HIV Infection · South Africa, Uganda | 3 | Active, not recruiting | Gilead Sciences | May 27, 2024 | 5,368 |
| NCT04661397Healthy · Netherlands | 1 | Completed | Johnson & Johnson | Jul 2, 2021 | 37 |
| NCT04388904Acquired Immunodeficiency Syndrome · United States | 4 | Completed | The Crofoot Research Center | Apr 5, 2024 | 75 |
| NCT04236453Healthy · Netherlands | 1 | Terminated | Johnson & Johnson | Apr 10, 2020 | 16 |
| NCT04201808Hepatitis B, Chronic · China | 4 | UNKNOWN | New Discovery | Sep 30, 2023 | 100 |
| NCT04143594HIV-1-infection · United States, Dominican Republic, Puerto Rico | 2 | Completed | Gilead Sciences | Oct 5, 2021 | 183 |
| NCT03960645HIV-1-infection · United States, Dominican Republic, Thailand | 1 | Completed | Gilead Sciences | Jul 21, 2022 | 62 |
| NCT03739866HIV-1 Infection · United States | 1 | Completed | Gilead Sciences | Nov 14, 2019 | 53 |
| NCT03631732HIV-1 Infection · United States | 3 | Completed | Gilead Sciences | Aug 12, 2019 | 496 |
| NCT03547908HIV-1/HBV Co-Infection · United States, China, Dominican Republic and more | 3 | Completed | Gilead Sciences | Feb 25, 2022 | 244 |
| NCT03434353Hepatitis B, Chronic · Hong Kong, Korea, Republic of | 2 | Terminated | Gilead Sciences | Jan 20, 2020 | 123 |
| NCT03405935HIV-1 Infection · Belgium, France, Italy and more | 3 | Completed | Gilead Sciences | Nov 20, 2018 | 86 |
| NCT03180619Hepatitis B, Chronic · United States, Canada, Hong Kong and more | 2 | Completed | Gilead Sciences | Mar 27, 2019 | 124 |
| NCT03110380HIV-1-infection · United States, Austria, Canada and more | 3 | Completed | Gilead Sciences | Dec 4, 2018 | 567 |
| NCT02984852Healthy · United States | 1 | Completed | Johnson & Johnson | Feb 2017 | 30 |
| NCT02932150Hepatitis B, Chronic · United States, Belgium, Hong Kong and more | 2 | Active, not recruiting | Gilead Sciences | Oct 27, 2026 | 150 |
| NCT02881320HIV-1 Infection · United States, South Africa, Thailand and more | 3 | Active, not recruiting | Gilead Sciences | Mar 24, 2025 | 177 |
| NCT02862548Hepatitis B, Chronic · New Zealand | 2 | Completed | Gilead Sciences | Feb 8, 2018 | 51 |
| NCT02842086Pre-Exposure Prophylaxis of HIV-1 Infection · United States, Austria, Canada and more | 3 | Terminated | Gilead Sciences | Jan 31, 2019 | 5,399 |
| NCT02836249Hepatitis · China | 3 | Completed | Gilead Sciences | Mar 21, 2017 | 181 |
| NCT02836236Hepatitis · China | 3 | Completed | Gilead Sciences | Apr 5, 2017 | 155 |
| NCT02707601Hepatitis C · United States, Puerto Rico | 3 | Completed | Gilead Sciences | Sep 14, 2017 | 150 |
| NCT02652624HIV-1 Infection · United States, Dominican Republic, Puerto Rico and more | 3 | Completed | Gilead Sciences | Oct 9, 2017 | 472 |
| NCT02616029HIV-1 Infection · United States, France, Germany and more | 3 | Completed | Gilead Sciences | Oct 11, 2018 | 66 |
| NCT02616783HIV-1 Infection · Belgium, France, Italy and more | 3 | Completed | Gilead Sciences | Feb 21, 2018 | 167 |
| NCT02605954HIV-1 Infection · United States, France, Germany and more | 3 | Completed | Gilead Sciences | Jun 14, 2017 | 275 |
| NCT02607956HIV-1 Infection · United States, Australia, Belgium and more | 3 | Completed | Gilead Sciences | May 12, 2017 | 657 |
| NCT02600819Kidney Failure, Chronic · United States, Austria, France and more | 3 | Completed | Gilead Sciences | Sep 29, 2017 | 55 |
| NCT02578550Acquired Immunodeficiency Syndrome · Netherlands | 1 | Completed | Johnson & Johnson | Feb 2016 | 126 |
| NCT02475135Acquired Immunodeficiency Syndrome · Belgium | 1 | Completed | Johnson & Johnson | Aug 14, 2015 | 72 |
| NCT02469246HIV-1 Infection · United States, Belgium, Canada and more | 3 | Completed | Gilead Sciences | Dec 11, 2017 | 567 |
| NCT02431247Acquired Immunodeficiency Syndrome · United States, Belgium, Canada and more | 3 | Completed | Johnson & Johnson | Mar 2, 2017 | 725 |
| NCT02397694HIV-1 Infection · United States | 2 | Completed | Gilead Sciences | Nov 30, 2015 | 98 |
| NCT02296853Hepatitis B · United States, Germany, New Zealand | 1 | Completed | Gilead Sciences | Apr 17, 2015 | 20 |
| NCT02276612HIV · United States, South Africa | 3 | Completed | Gilead Sciences | Nov 10, 2016 | 60 |
| NCT02269917Acquired Immunodeficiency Syndrome · United States, Belgium, Canada and more | 3 | Completed | Johnson & Johnson | Feb 2017 | 1,149 |
| NCT02121795HIV-1 Infection · United States, Belgium, Canada and more | 3 | Completed | Gilead Sciences | Aug 12, 2015 | 668 |
| NCT02071082Coinfection · United States, Canada, Japan | 3 | Completed | Gilead Sciences | Jan 23, 2015 | 79 |
| NCT02016924Acquired Immunodeficiency Syndrome · United States, Argentina, South Africa and more | 3 | Active, not recruiting | Gilead Sciences | Jun 13, 2025 | 133 |
| NCT01967940HIV Infections · United States, Dominican Republic, Russian Federation and more | 3 | Completed | Gilead Sciences | May 21, 2015 | 55 |
| NCT01968551HIV Infections · United States, Canada | 3 | Completed | Gilead Sciences | Jul 21, 2015 | 158 |
| NCT01940471Hepatitis · United States, Australia, Bulgaria and more | 3 | Completed | Gilead Sciences | Nov 16, 2015 | 875 |
| NCT01940341Hepatitis · United States, Australia, Canada and more | 3 | Completed | Gilead Sciences | Sep 30, 2015 | 426 |
| NCT01854775Acquired Immunodeficiency Syndrome · United States, South Africa, Thailand and more | 3 | Completed | Gilead Sciences | May 11, 2020 | 129 |
| NCT01818596HIV Infections · United States, Australia, Dominican Republic and more | 3 | Completed | Gilead Sciences | Jul 31, 2014 | 252 |
| NCT01815736HIV Infections · United States, Australia, Austria and more | 3 | Completed | Gilead Sciences | Mar 16, 2015 | 1,443 |
| NCT01797445HIV Infections · United States, Canada, Dominican Republic and more | 3 | Completed | Gilead Sciences | Sep 19, 2014 | 872 |
| NCT01780506HIV Infections · United States, Australia, Austria and more | 3 | Completed | Gilead Sciences | Aug 26, 2014 | 872 |
| NCT01671787Hepatitis B, Chronic · United States, Australia, Canada and more | 1 | Completed | Gilead Sciences | Apr 2013 | 51 |
| NCT01565850Acquired Immunodeficiency Syndrome · United States, Puerto Rico | 2 | Completed | Gilead Sciences | Jan 2013 | 153 |
| NCT01497899Acquired Immunodeficiency Syndrome · United States, Puerto Rico | 2 | Completed | Gilead Sciences | Oct 17, 2012 | 279 |
How it is read
Names in the registry
- “E/C/F/TAF”, 17 entries
- “TAF”, 12 entries
- “B/F/TAF”, 10 entries
- “F/TAF”, 8 entries
- “B/F/TAF (TOS)”, 4 entries
Conditions, from the studies’ own filings
- Acquired Immunodeficiency Syndrome, 11 studies
- Hepatitis B, Chronic, 10 studies
- HIV Infections, 7 studies
- Hepatitis, 4 studies
- Coinfection, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.